161 related articles for article (PubMed ID: 36989376)
1. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.
Ricciardi MJ; Rust LN; Pedreño-Lopez N; Yusova S; Biswas S; Webb GM; Gonzalez-Nieto L; Voigt TB; Louw JJ; Laurino FD; DiBello JR; Raué HP; Barber-Axthelm AM; Chun K; Uttke S; Raphael LMS; Yrizarry-Medina A; Rosen BC; Agnor R; Gao L; Labriola C; Axthelm M; Smedley J; Julander JG; Bonaldo MC; Walker LM; Messaoudi I; Slifka MK; Burton DR; Kallas EG; Sacha JB; Watkins DI; Burwitz BJ
Sci Transl Med; 2023 Mar; 15(689):eade5795. PubMed ID: 36989376
[TBL] [Abstract][Full Text] [Related]
2. Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
Doyle MP; Genualdi JR; Bailey AL; Kose N; Gainza C; Rodriguez J; Reeder KM; Nelson CA; Jethva PN; Sutton RE; Bombardi RG; Gross ML; Julander JG; Fremont DH; Diamond MS; Crowe JE
mBio; 2022 Jun; 13(3):e0051222. PubMed ID: 35420472
[TBL] [Abstract][Full Text] [Related]
3. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
4. A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.
Calvert AE; Dixon KL; Piper J; Bennett SL; Thibodeaux BA; Barrett AD; Roehrig JT; Blair CD
Antiviral Res; 2016 Jul; 131():92-9. PubMed ID: 27126613
[TBL] [Abstract][Full Text] [Related]
5. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
6. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
8. Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.
Julander JG; Thibodeaux BA; Morrey JD; Roehrig JT; Blair CD
Antiviral Res; 2014 Mar; 103():32-8. PubMed ID: 24393669
[TBL] [Abstract][Full Text] [Related]
9. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.
Avelino-Silva VI; Miyaji KT; Hunt PW; Huang Y; Simoes M; Lima SB; Freire MS; Caiaffa-Filho HH; Hong MA; Costa DA; Dias JZ; Cerqueira NB; Nishiya AS; Sabino EC; Sartori AM; Kallas EG
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005219. PubMed ID: 27941965
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
11. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
[TBL] [Abstract][Full Text] [Related]
12. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
[TBL] [Abstract][Full Text] [Related]
13. Absence of YF-neutralizing antibodies in vulnerable populations of Brazil: A warning for epidemiological surveillance and the potential risks for future outbreaks.
Stoffella-Dutra AG; Silva de Oliveira J; Barbosa Costa G; Geessien Kroon E; Santos Abrahão J; Desiree LaBeaud A; Paiva Drumond B; Bretas de Oliveira D; de Souza Trindade G
Vaccine; 2020 Sep; 38(42):6592-6599. PubMed ID: 32788140
[TBL] [Abstract][Full Text] [Related]
14. Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope.
Lu X; Xiao H; Li S; Pang X; Song J; Liu S; Cheng H; Li Y; Wang X; Huang C; Guo T; Ter Meulen J; Daffis S; Yan J; Dai L; Rao Z; Klenk HD; Qi J; Shi Y; Gao GF
Cell Rep; 2019 Jan; 26(2):438-446.e5. PubMed ID: 30625326
[TBL] [Abstract][Full Text] [Related]
15. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW
J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183
[TBL] [Abstract][Full Text] [Related]
16. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.
Slifka MK; Leung DY; Hammarlund E; Raué HP; Simpson EL; Tofte S; Baig-Lewis S; David G; Lynn H; Woolson R; Hata T; Milgrom H; Hanifin J
J Allergy Clin Immunol; 2014 Feb; 133(2):439-47. PubMed ID: 24331381
[TBL] [Abstract][Full Text] [Related]
17. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
[TBL] [Abstract][Full Text] [Related]
18. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.
Thibodeaux BA; Garbino NC; Liss NM; Piper J; Schlesinger JJ; Blair CD; Roehrig JT
Antiviral Res; 2012 Apr; 94(1):1-8. PubMed ID: 22366350
[TBL] [Abstract][Full Text] [Related]
19. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
Kleinert RDV; Montoya-Diaz E; Khera T; Welsch K; Tegtmeyer B; Hoehl S; Ciesek S; Brown RJP
Viruses; 2019 Oct; 11(10):. PubMed ID: 31627415
[TBL] [Abstract][Full Text] [Related]
20. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
